WO2009119891A1 - Dnaメチル化測定方法 - Google Patents
Dnaメチル化測定方法 Download PDFInfo
- Publication number
- WO2009119891A1 WO2009119891A1 PCT/JP2009/056785 JP2009056785W WO2009119891A1 WO 2009119891 A1 WO2009119891 A1 WO 2009119891A1 JP 2009056785 W JP2009056785 W JP 2009056785W WO 2009119891 A1 WO2009119891 A1 WO 2009119891A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- region
- methylated
- base sequence
- seq
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
Definitions
- the present invention relates to a method for measuring the content of methylated DNA in a target DNA region in genomic DNA contained in a biological specimen.
- the content of methylated DNA in the target DNA region in the genomic DNA See, for example, Nucleic Acids Res. 1994 Aug 11; 22 (15): 2990-7, and Proc Natl Acad Sci US A. 1 997 Mar 18; 94 (6): 2284-9) .
- this measurement method first, it is necessary to extract DNA containing the target DNA region from a DNA sample derived from genomic DNA, and the extraction operation is complicated.
- a method for measuring the content of methylated DNA in the target region of the extracted DNA for example, (1) DNA modification using sulfite, etc., followed by DNA synthesis by DNA polymerase (2) A method of amplifying the target region by subjecting it to a chain reaction (hereinafter also referred to as PCR). (2) Digesting the DNA with a methylation-sensitive restriction enzyme, followed by PCR. A method for amplifying a target region by providing the information is known. Both of these methods require labor for modification of DNA for detection of methinorelation and subsequent purification of the product, preparation of a reaction system for PCR, confirmation of DNA amplification, and the like. Disclosure of the invention
- An object of the present invention is to provide a method for easily measuring the content of methylated DNA in the target DNA region in the genomic DNA contained in a biological sample.
- the following inventions are provided. [Invention 1]
- a method for measuring the content of methylated DNA in a target DNA region in genomic DNA contained in a biological specimen A method for measuring the content of methylated DNA in a target DNA region in genomic DNA contained in a biological specimen
- first pre-process The process of making single-stranded DNA (primary strand) (first pre-process) and 'genome-derived DNA (positive strand) that was made single-stranded in the first pre-process, A partial base sequence (positive strand) of the base sequence of the DNA (positive strand) in the state, and 3 'end further than the 3, end of the base sequence (positive strand) of the target DNA region Extension primer (forward primer) having a partial base sequence (positive strand) located on the side and a base sequence (negative strand) that is complementary to And extending the extension primer once to extend a single-stranded DNA (positive strand) containing the target DNA region into a double-stranded DNA (second pre-step),
- the double-stranded DNA formed by extension in the second previous step contains a single-stranded DNA (positive strand) containing the target DNA region and a base sequence that is complementary to the target DNA region. It has a process (third pre-process) that separates into single-stranded DNA (negative chain) once.
- Step A in which single-stranded DNA containing the DNA region
- a single-stranded DNA (negative strand) containing a base sequence that is complementary to the generated target DNA region in a saddle shape, and a base that is complementary to the target DNA region A partial base sequence (negative strand) of the base sequence of the single-stranded DNA (negative strand) containing the sequence, and complementary to the base sequence (positive strand) of the target DNA region base
- step B this step in which the extension primer is extended once, thereby extending the single-stranded DNA containing the target DNA region as a double-stranded DNA.
- each step of the third step is repeated once after separating the elongated double-stranded DNA obtained in each step into a single-stranded state, and thereby to the target DNA region.
- a third step of amplifying the methylated DNA to a detectable amount and quantifying the amount of amplified DNA is repeated once after separating the elongated double-stranded DNA obtained in each step into a single-stranded state, and thereby to the target DNA region.
- a third step of amplifying the methylated DNA to a detectable amount and quantifying the amount of amplified DNA.
- a DNA sample derived from genomic DNA contained in a biological sample is a DNA sample that has been previously digested with a restriction enzyme that does not use the target DNA region of the genomic DNA as a recognition cleavage site, or has been purified in advance.
- the first step is
- the first (B) step of digesting the single-stranded DNA selected in the first (A) step with a methylation sensitive restriction enzyme and the invention according to any one of inventions 1 to 4, comprising Method.
- invention 6 The method according to any one of Inventions 1 to 5, wherein the methylation-sensitive restriction enzyme is a restriction enzyme having a recognition cleavage site in a target DNA region of genomic DNA contained in a biological specimen, or Hhal. .
- the second step is
- the second (A) step comprises the second (B) step of binding the methylated single-stranded DNA obtained in step (A) and the immobilized methyl ⁇ DN A antibody.
- FIG. 1 shows that in Example 1, methylated DNA in the region consisting of the nucleotide sequence represented by SEQ ID NO: 23 was amplified from the prepared sample by PCR, and the obtained amplification product was subjected to 2% agarose gel electrophoresis. It is the figure which showed the result.
- DNA marker “MK:” partially methylated oligonucleotide methylated with recognition sequence of Hpa II GPR 7— 2079-21 76 / 98me r M (7)
- Sampnole treated with “A” solution “HJ” unmethylated oligonucleotide GPR 7—2079—21 76 / 98me ri
- FIG. 2 shows the amplification of the methylated DNA in the target DNA region consisting of the nucleotide sequence shown in SEQ ID NO: 28 from the sample prepared in Example 2 by PCR.
- FIG. 5 shows the results of 5% agarose gel electrophoresis. From leftmost lane in the figure, DNA marker “MK”, methylated DNA fragment MX solution “MD” (negative control), unmethylated DNA fragment X solution “D” (Negative control), methylated DNA fragment MX solution “MC”, unmethylated DNA fragment X solution “C”, methylated DNA fragment MX solution “MB”, methylated The results are shown in solution “B” for DNA fragment X, “MA” for methylated DNA fragment MX, solution “A” for unmethylated DNA fragment X, “B”.
- Figure 3 shows the amplification product obtained in Example 3 by amplifying methylated DNA in the target DNA region consisting of the nucleotide sequence represented by SEQ ID NO: 45 from the prepared sample by PCR.
- FIG. 6 is a view showing the results of 5% agarose gel electrophoresis.
- FIG. 4 shows the amplification of the methylated DNA in the target DNA region consisting of the nucleotide sequence shown in SEQ ID NO: 53 from the sample prepared in Example 4 by PCR.
- FIG. 5 shows the results of 5% agarose gel electrophoresis.
- FIG. 5 shows the amplification product obtained by amplifying the methylated DNA in the target DNA region consisting of the base sequence represented by SEQ ID NO: 53 in Example 5 by PCR from the prepared sample, and 1.
- DNA marker “MK:” methylated yeast genomic DNA solution “MD” (negative control), unmethylated yeast genomic DNA solution “D” (negative control)
- Methylated yeast genomic DNA solution “MC” Unmethylated yeast genomic DNA solution “C”
- Methylated yeast genomic DNA solution “MB” Unmethylated yeast genomic DNA solution “MC” B
- solution of methylated yeast genomic DNA” MA solution of unmethylated yeast genomic DNA “A” shows the results for and.
- tissue has a broad meaning including blood, lymph nodes, etc.
- biological samples such as plasma, serum, and lymph fluid, body secretions (such as urine and milk), and genomic DNA obtained by extraction from these biological samples.
- biological specimen include samples derived from microorganisms, viruses, etc.
- genomic DNAJ in the present invention means the genomic DNA of microorganisms and viruses.
- DNA may be extracted using a commercially available DNA extraction kit.
- plasma or serum is prepared from blood according to a conventional method, and the prepared plasma or serum is used as a specimen, and free DNA contained therein (cancer cells such as gastric cancer cells).
- cancer cells such as gastric cancer cells.
- the genomic DNA-derived DNA sample may be a DNA sample that has been previously digested with a restriction enzyme that does not use the target DNA region of the genomic DNA, which will be described later, as a recognition cleavage site, or a predetermined method. It can be a DNA sample that has been purified in advance. Normally, there are four types of bases that make up a gene (genomic DNA). Of these bases, it is known that only cytosine is methylated, and such DNA methylation modification is based on the nucleotide sequence represented by 5 '— CG—3, where C represents cytosine. , G stands for Gwan, and the base sequence is sometimes referred to as “CpG.” This is limited to cytosines.
- cytosine The site that is methylated in cytosine is at position 5.
- “methylated DN Aj and Means DNA produced by such methylation modification “methylated DN Aj and Means DNA produced by such methylation modification.
- the “C p G pair” in the present invention means a double-stranded oligonucleotide formed by base pairing of a base sequence represented by C p G and a complementary C p G.
- the “target DNA region” in the present invention (hereinafter sometimes referred to as a target region) is a DNA region to be examined for the presence or absence of methylation of cytosine contained in the region, and is at least one kind of DNA region. Has a recognition site for a methylation sensitive restriction enzyme. For example, Lysy 1 oxidase, HRAS-like suppressor bA305P22. 2.
- the base sequence shown by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region)
- the base sequence containing one or more include the base sequence of genomic DNA containing exon 1 of the human Lysyl oxidase gene and the promoter region located 5 'upstream thereof.
- the nucleotide sequence represented by SEQ ID NO: 1 (the nucleotide sequence described in Genbank Accession No. AF270645) This corresponds to the base sequence represented by base numbers 16001 to 18661. ).
- the ATG codon that encodes the amino terminal methionine of Lysyl oxidase protein derived from human is represented by nucleotide numbers 2031 to 2033.
- the nucleotide sequence of the above exon 1 is represented by nucleotide number 1957-2661.
- the cytosine in G exhibits a high methylation frequency (ie, hypermethylation) in cancer cells such as gastric cancer cells.
- cytosine with high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 1, base numbers 1539, 1560, 1574, 1600, 1623, 1635, 1644, 1654, 1661, Examples include cytosine represented by 1682, 1686, 1696, 1717, 1767, 1774, 1783, 1785, 1787, 1795, and the like.
- the useful protein gene is HRAS-like suppressor gene, it is represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- the base sequence of genomic DNA containing exon 1 of the HRAS-like suppressor gene derived from human and a promoter region located 5 ′ upstream thereof can be mentioned, More specifically, the base sequence represented by SEQ ID NO: 2 (corresponding to the base sequence represented by base numbers 172001 to 173953 of the base sequence described in Genbank Accession No. AC068162) can be mentioned. In the base sequence represented by SEQ ID NO: 2, the base sequence of exon 1 of the human-derived HRAS-like suppress or gene is represented by base numbers 1743-1953.
- cytosine having high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 2, base numbers 1316, 1341, 1357, 1359, 1362, 1374, 1390, 1399, 1405, 1409 , 1414, 1416, 1422, 1428, 1434, 1449, 1451, 1454, 1463, 1469, 1477, 1479, 14 83, 1488, 1492, 1494, 1496, 1498, 1504, 1510, 1513, 1518, 1520, etc. Can be given.
- the useful protein gene when the useful protein gene is bA305P22.2.1 gene, it is indicated by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- Examples of nucleotide sequences that include one or more nucleotide sequences include those of genomic DNA containing human exon 1 of bA 3 05P22.2. 1 gene and the 5 'upstream promoter region. More specifically, the base sequence represented by SEQ ID NO: 3 (corresponding to the base sequence represented by base numbers 13001 to 13889 of the base sequence described in Genbank Accession No. AL121673) can be mentioned.
- the ATG codon encoding the methionine at the amino amino terminal of the human-derived bA305P22.2.1 protein is shown in base numbers 849 to 851, and the base sequence of exon 1 above is shown. Is shown in base numbers 663-889.
- the cytosine in G shows a high methylation frequency (ie, hypermethylation) in cancer cells such as gastric cancer cells.
- cytosine having a high frequency of metinorelation in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 3, base numbers 329, 335, 337, 351, 363, 373, 405, 424, 427 , 446, 465, 472, 486, and the like.
- the useful protein gene is a Gamma filamin gene, it is represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- a base sequence containing one or more base sequences a genomic DNA base sequence containing exon 1 of a human-derived Gamma filamin gene and a promoter region located 5 ′ upstream thereof can be mentioned.
- the base sequence represented by SEQ ID NO: 4 (base described in Genbank Accession No. AC074373) It corresponds to a complementary sequence of the base sequence represented by base numbers 63528 to 64390 of the sequence. ).
- the ATG codon encoding the amino terminal methionine of the Gamma filamin protein derived from human is shown in base numbers 572 to 574.
- the base sequence of exon 1 is Base numbers 463 to 863.
- cytosine having a high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 4, base numbers 329, 333, 337, 350, 353, 360, 363, 370, 379.
- Examples include cytosine represented by 382, 384, 409, 414, 419, 426, 432, 434, 445, 449, 459, 472, 474, 486, 490, 503, 505, and the like.
- the useful protein gene is HA D1 gene
- the base sequence represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- a base sequence S of genomic DNA containing exon 1 of the HAND1 gene derived from human and its promoter region located upstream of it can be mentioned. Includes a base sequence represented by ⁇ & column number 5 (corresponding to a complementary sequence of the base sequence represented by base numbers 243 03 to 26500 of the base sequence described in Genbank Accession No. 'AC026688). .
- the ATG codon encoding the amino acid at the amino terminal of the HAND1 protein derived from human is represented by nucleotide numbers 1656 to 1658.
- the nucleotide sequence of exon 1 is The number 1400-2198 is shown.
- the cytosine in G shows a high methylation frequency (ie, hypermethylation) in cancer cells such as gastric cancer cells. More specifically, as cytosine having a high methylation frequency in gastric cancer cells, for example, in the base sequence represented by SEQ ID NO: 5, No. 1153, 1160, 1178, 1187, 1193, 1218, 1232, 1266, 1272, 1292, 1305, 1307, 13 16, 1356, 1377, 1399, 1401, 1422, 1434, etc. .
- the useful protein gene is the Homologue of RIKEN 2210016F16 gene
- the base sequence containing one or more base sequences indicated by G includes the base sequence of genomic DNA containing exon 1 of the human-derived Homologue of RIKEN 2210016F16 gene and the promoter region located 5 ′ upstream thereof.
- the nucleotide sequence represented by SEQ ID NO: 6 the complementary nucleotide sequence of the nucleotide sequence represented by nucleotide numbers 157056 to 159000 of the nucleotide sequence described in Genbank Accession No. AL354733) Equivalent
- the base sequence IJ of exon 1 of the human-derived Homologue of RIKEN 2210016F16 gene is represented by base numbers 1392 to 1945.
- the cytosine in G shows a high methylation frequency (ie, hypermethylation) in cancer cells such as gastric cancer cells.
- cytosine having a high methyline frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 6, the base numbers 1172, 1175, 1180, 1183, 1189, 1204, 1209, 1267, 1271, Examples include 1278, 1281, 1313, 1319, 1332, 1334, 1338, 1346, 1352, 1358, 1366, 1378, 1392, 1402, 1433, 1436, 1438, and the like.
- the base sequence represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region) is Examples of the nucleotide sequence containing one or more include the nucleotide sequence of genomic DNA containing exon 1 of the FLJ32130 gene derived from human and its promoter region located upstream of the gene. More specifically, In SEQ ID NO: 7 (Corresponding to a complementary nucleotide sequence of the nucleotide sequence represented by nucleotide numbers 1 to 2379 of the nucleotide sequence described in Genbank Accession No. AC002310).
- nucleotide sequence represented by SEQ ID NO: 7 the ATG codon encoding the methionine at the amino acid end of the FLJ32130 protein derived from human is represented by nucleotide numbers 2136 to 2138, and the nucleotide sequence considered to be exon 1 is Base numbers 2136 to 2379 are shown.
- cytosine in pG shows a high frequency of methine leihi (ie, hypermethylation) in cancer cells such as gastric cancer cells.
- cytosine having high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 7, base numbers 1714, 1716, 1749, 1753, 1762, 1795, 1814, 1894 1911, 1915, 1925, 1940, 1955, 1968 and the like.
- the useful protein gene is a PPARG angiopoietin-related protein gene
- the base sequence containing one or more base sequences represented by G includes genomic DNA bases containing exon 1 of human-derived PPARG angiopoietin-related protein gene, its 5, promoter region located upstream.
- the base sequence shown in SEQ ID NO: 8 can be mentioned.
- ATG codon encoding Mechionin of Amino-terminal of PPARG angio P oietin-r elated protein protein from human is represented in salt group number 717-719, the Ekuson
- the base sequence of the 5 ′ side part of 1 is shown in base numbers 1957 to 2661. Cytosine in the base sequence shown by C p G present in the base sequence shown in SEQ ID NO: 8, particularly C p G present in the region where C p G is densely present in the base sequence shown in SEQ ID NO: 8.
- the cytosine in the middle shows high methylation frequency (ie, hypermethylation) in cancer cells such as gastric cancer cells. More specifically, as cytosine with high methylation frequency in gastric cancer cells, for example, in the base sequence represented by SEQ ID NO: 8, base numbers 35, 43, 51, 54, 75, 85 107, 127, 129, 143, 184, 194, 223, 227, 236, 251, 258 and the like. More specifically, for example, when the useful protein gene is a Throtnbomodulin gene, it is represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- nucleotide sequence containing one or more nucleotide sequences examples include the genomic DNA nucleotide sequence containing exon 1 of the Thrombomodulin gene derived from human and 5, a promoter region located upstream.
- the base sequence represented by SEQ ID NO: 9 (corresponding to the base sequence represented by base numbers 1 to 6096 of the base sequence described in Genbank Accession No. AF495471) can be mentioned.
- the ATG codon encoding the amino terminal methionine of the human Thrombomodulin protein is represented by nucleotide numbers 2590 to 2592.
- the nucleotide sequence of the above exon 1 is Base numbers 2048-6096 are shown.
- cytosine having a high methylation frequency in gastric cancer cells for example, in the base sequence represented by SEQ ID NO: 9, the base numbers 1539, 1551, 1571, 1579, 1581, 1585, 1595, 1598, 1.601 1621, 1632, 1638, 1645, 1648, 1665, 1667, 1680, 1698, 1710, 1724, 1726, 1756, and the like.
- the useful protein gene is p53-responsive gene 2 gene, it is C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- nucleotide sequence containing one or more of the nucleotide sequences shown include those of genomic DNA containing exon 1 of human-derived p53-responsive gene 2 gene and a promoter region located 5 'upstream thereof. More specifically, the nucleotide sequence represented by SEQ ID NO: 10 (Genbank Accession No. AC00947 1 corresponds to a complementary sequence of the base sequence represented by base numbers 113501 to 116000 of the base sequence described in 1. ). In the nucleotide sequence represented by SEQ ID NO: 10, the nucleotide sequence of exon 1 of the human-derived p53-responsive gene 2 gene is represented by nucleotide numbers 1558 to 1808.
- Cytosine in the base sequence represented by C p G present in the base sequence represented by SEQ ID NO: 10 has a high methylation frequency (ie, hypermethylation state in cancer cells such as knee cancer cells). hypermethylation)). More specifically, cytosine having a high methylation frequency in spleen cancer cells, for example, in the base sequence represented by SEQ ID NO: 10, base numbers 1282, 1284, 1301, 1308, 1315, 1319, 1349, The cytosine shown by 1351, 1357, 1361, 1365, 1378, 1383 etc. can be mentioned.
- the base sequence represented by C p G present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- the nucleotide sequence containing one or more of the above include the nucleotide sequence of genomic DNA containing exon 1 of the Fibrillin2 gene derived from human, and its promoter region located upstream of the gene. Is a base sequence represented by SEQ ID NO: 11 (corresponding to a complementary sequence of the base sequence represented by base numbers 118801 to 121000 of the base sequence described in Genbank Accession No. AC113387).
- nucleotide sequence represented by SEQ ID NO: 11 the nucleotide sequence of exon 1 of the human-derived Fibrillin gene is represented by nucleotide numbers 1091 to 1345.
- Cytosine in the base sequence represented by C p G present in the base sequence represented by SEQ ID NO: 1 1 has a high methylation frequency (ie, hypermethylation state ( hypermethylati on)).
- cytosine having a high methylation frequency in the spleen cancer cells for example, in the base sequence represented by SEQ ID NO: 11, the base numbers 679, 687, 690, 699, 746, 773, 777, 783 795, 799, 812, 823, 830, 834, 843, and the like.
- the useful protein gene is a Neurofilament 3 gene
- the base sequence containing one or more base sequences represented by CG in the base sequence includes genomic DNA containing exon 1 of the human-derived neurofilaments gene, and a promoter region located upstream of it.
- the base sequence represented by SEQ ID NO: 12 corresponds to a complementary sequence.
- the nucleotide sequence represented by SEQ ID NO: 12 the nucleotide sequence of exon 1 of the human-derived Neurofilaments gene is represented by nucleotide numbers 614 to 1694.
- cytosine in the nucleotide sequence represented by C p G present in the nucleotide sequence represented by SEQ ID NO: 1 2 has a high methylation frequency (ie, hypermethylation state ( hypermethylation)).
- cytosine with high methylation frequency in spleen cancer cells for example, in the base sequence represented by SEQ ID NO: 12, base numbers 428, 432, 443, 451, 471, 475, 482, Examples include cytosine represented by 491, 499, 503, 506, 514, 519, 532, 541, 544, 546, 563, 566, 572, 580, and the like.
- the nucleotide sequence containing one or more nucleotide sequences represented by is a genomic DNA nucleotide sequence containing exon 1 of the human-derived disintegrin and metalloproteinase doma in 23 gene and a promoter region located 5 ′ upstream thereof. More specifically, the nucleotide sequence represented by SEQ ID NO: 13 (corresponding to the nucleotide sequence represented by nucleotide numbers 21001 to 23300 of the nucleotide sequence described in Genbank Accession No. AC009225). ).
- nucleotide sequence IJ represented by SEQ ID NO: 13 the base sequence of exon 1 of the human-derived disintegrin and metalloproteinase domain 23 gene is represented by nucleotide numbers 1194 to 1630.
- cytosine in the base sequence represented by CpG present in the base sequence represented by SEQ ID NO: 13 has a high methylation frequency (ie, hypermethylation state in cancer cells such as spleen cancer cells).
- cytosine having a high methylation frequency in knee cancer cells for example, in the base sequence represented by SEQ ID NO: 13 998, 1003, 1007, 1011, 1016, 1018, 1020, 1026, 1028, 1031, 1035, 1041, 1043, 1045, 1051, 1053, 1056, 1060, 1066, 1068, 1070, 1073, 1093, 1096, 1106, 11 12, 1120, 1124, 1126 and the like can be mentioned.
- the useful protein gene is a G protein-coupled receptor 7 gene, it is a CG present in the base sequence of the promoter region, untranslated region or translated region (coding region).
- the nucleotide sequence containing one or more of the nucleotide sequences shown is the nucleotide sequence of genomic DNA containing exon 1 of the human G protein-coupled receptor 7 gene, and its upstream promoter region. More specifically, the base sequence represented by SEQ ID NO: 14 (corresponds to the base sequence represented by base numbers 75001 to 78000 of the base sequence described in Genbank Accession No. AC009800). can give. In the nucleotide sequence represented by SEQ ID NO: 14, the nucleotide sequence of exon 1 of G protein-coupled receptor 7 gene derived from human is represented by nucleotide numbers 1666 to 2652.
- Cytosine in the base sequence represented by C p G present in the base sequence represented by SEQ ID NO: 14 is, for example, a high methylation frequency (ie, hypermethylated state) in cancer cells such as presumptive cancer cells. (Hypermethylation)). More specifically, as cytosine having high methylation frequency in knee cancer cells, for example, in the base sequence represented by SEQ ID NO: 14, base numbers 1480, 1482, 1485, 1496, 1513, 1526, 1542, 1560 1564, 1568, 1570, 1580, 1590, 1603, 1613, 1620 and the like.
- a useful protein gene is a G-protein coupled somatostat in and angiotensin-like peptide receptor ⁇ is a child, its promoter region, untranslated region or translation region
- the base sequence that contains one or more base sequences indicated by C p G present in the base sequence of the region (coding region) is human exogenous G-protein coupled somatostatin and angiotensin-like peptide receptor gene 1
- the nucleotide sequence of the genomic DNA containing the promoter region located upstream thereof, and more specifically, the salt represented by SEQ ID NO: 15 A base sequence (corresponding to a complementary sequence of the base sequence represented by base numbers 57001 to 60 000 of the base sequence described in Genbank Accession No.
- the nucleotide sequence of exon 1 of G-protein coupled somatostatin and ang iotensin-like peptide receptor gene derived from baboon is represented by nucleotide numbers 776-2632.
- Cytosine in the base sequence represented by C p G present in the base sequence represented by SEQ ID NO: 15 is, for example, a high methylation frequency (ie, hypermethylated state) in cancer cells such as knee cancer cells. (Hypermethylation)).
- cytosine having a high methyl baboon frequency in knee cancer cells for example, in the base sequence represented by SEQ ID NO: 15, the base numbers 470, 472, 490, 497, 504, 506, 509, 514, The cytosine shown by 522, 540, 543, 552, 566, 582, 597, 610, 612 etc. can be mentioned. More specifically, for example, when the useful protein gene is Solute carrier family 6 neurotransmitter transporter noradrenalm member 2, the nucleotide sequence of the promoter region, untranslated region or translated region (coding region).
- the base sequence including one or more base sequences represented by C p G in it includes the human-derived Solute carrier family 6 neurotransmitter transporter noradrenalm member 2 and the exon 1 of the remaining 5 'upstream. And more specifically, the nucleotide sequence of SEQ ID NO: 16 (base number 78801 to the nucleotide sequence described in Genbank Accession No. AC026802). This corresponds to a complementary sequence of the base sequence represented by 81000.
- the nucleotide sequence of exon 1 of the human-derived Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene is represented by nucleotide numbers 1479-1804 as shown in SEQ ID NO: 16 Has been.
- Cytosine in the base sequence represented by C p G present in the base sequence represented by SEQ ID NO: 16 is, for example, a high methylation frequency (ie, hypermethylation state in cancer cells such as knee cancer cells). )) More specifically, as cytosine having a high methylation frequency in spleen cancer cells, for example, in the base sequence represented by SEQ ID NO: 16, base numbers 1002, 1010, 1019, 1021, 1051, 1056, 1061, 1063, The cytosine shown by 1080, 1099, 1110, 1139, 1141, 1164, 1169, 1184 etc. can be mentioned.
- Methods of Methods means an antibody that binds a methylated base in DNA as an antigen.
- a specific example is a methylcytosine antibody that has the property of recognizing and binding to cytosine methylated at the 5-position in single-stranded DNA.
- Even a commercially available methylated DNA antibody may be any antibody that can specifically recognize and bind to methylated DNA described in this patent.
- a methylated DNA antibody can be prepared by a conventional method using a methylated base, methylated DNA or the like as an antigen. Specifically, in order to prepare a methylcytosine antibody, a specific antibody from an antibody prepared using 5-methylcytidine, 5-methylcytosine, or DNA containing 5-methylcytosine as an antigen to methylcytosine in DNA It can be produced by selecting the appropriate bond as an index.
- the antibodies obtained by immunizing animals with antigens include immunization with purified antigens, followed by the use of antibodies from the IgG fraction (polyclonal antibodies), and antibodies that produce single clones (monoclonal antibodies). ) Is available.
- polyclonal antibodies antibodies that produce single clones
- monoclonal antibodies antibodies that produce single clones
- Is available it is desirable that the antibody is capable of specifically recognizing methylated DNA or methylcytosine, and therefore it is desirable to use a monoclonal antibody.
- An example of a method for producing a monoclonal antibody is a cell fusion method.
- spleen cells B cells
- myeloma cells fused together to produce a hyperidoma
- the antibodies produced by the hyperidoma are selected and methylcytosine antibodies are selected.
- Monoclonal antibody can be prepared.
- 5-methylcytidine, 5-methylcytosine, or a mixture of DNA containing 5-methylcytosine is used as an antigen and administered to animals used for immunization. it can.
- 5-methylcytidine, 5-methylcytosine, or DNA containing 5-methylcytosine is directly administered to a mouse producing an antibody. If it is difficult to produce antibodies, support the antigen. It may be immunized by binding to a carrier.
- an adjuvant solution for example, a mixture of fluid paraffin and A race 1 A and a mixture of dead bacteria of Mycobacterium tuberculosis as an adjuvant
- immunization by incorporating it into a ribosome, Can increase immunity.
- a solution containing the antigen and an adjuvant solution in equal amounts and make it sufficiently milky then inject it subcutaneously or intraperitoneally into the mouse, or mix well with alum water, and then kill Bordetella pertussis as an adjuvant.
- a method of adding It is also possible to boost the mouse intraperitoneally or intravenously after an appropriate period after the first immunization.
- a solution in which the antigen is suspended may be directly injected into the mouse spleen for immunization.
- the spleen is removed and the adipose tissue is removed, and then a spleen cell suspension is prepared.
- the spleen cells are fused with, for example, HGPRT-deficient myeloma cells to produce a hybridoma.
- Any cell fusion agent may be used as long as it can efficiently fuse spleen cells (B cells) and myeloma cells.
- a method using Sendai virus (HV J) or polyethylene glycol (PEG) may be used.
- cell fusion may be performed by a method using a high voltage pulse. '
- An antigen-antibody reaction system can be used for the antibody detection method and antibody titer measurement method for selecting a hybridoma producing the desired antibody.
- Specific examples of antibody measurement methods for soluble antigens include radioisotope immunoassay (RIA) and enzyme immunoassay (ELISA).
- methyli-ligated single-stranded DNA in the present invention means single-stranded DNA in which C p G present in the single-stranded DNA is methylated at more than one site. It is not limited to single-stranded DNA in which all CpGs present in single-stranded DNA are methylated.
- amplified methylated DNA in the target DNA region to a detectable amount and the amount of amplified DNA refers to the amount of genomic DNA contained in a biological sample.
- the biological specimen is 1 mL of serum
- a DNA sample derived from genomic DNA contained in a biological specimen is digested with a methylation sensitive restriction enzyme.
- “Methylation-sensitive restriction enzyme” means, for example, a restriction enzyme that can digest only a recognition sequence containing unmethylated cytosine without digesting a recognition sequence containing methylated cytosine. . That is, in the case of DNA in which the cytosine contained in the recognition sequence that can be originally recognized by the methylation-sensitive restriction enzyme is methylated, even if the methyli koji sensitive restriction enzyme acts on the DNA, The DNA is not cleaved. On the other hand, when the cytosine contained in the recognition sequence that can be originally recognized by the methylation-sensitive restriction enzyme is not methylated, the methylation-sensitive restriction enzyme is allowed to act on the DNA. The DNA is cleaved.
- methylation-sensitive enzymes include, for example, HpaII, BstUI, Narl, which are restriction enzymes having a recognition cleavage site in the target DNA region of genomic DNA contained in a biological specimen. , SacII, Hhal and the like.
- the methylation sensitive restriction enzyme is already
- the methylation sensitive restriction enzyme does not cleave the methylated DNA! / It can be discriminated whether or not cytosine in the C p G pair existing in the recognition site of the methylation-sensitive restriction enzyme in the genomic DNA contained in the biological specimen has been methylated. That is, at least one C p existing in the recognition site of the methylation-sensitive restriction enzyme in the genomic DNA contained in the biological specimen is removed by performing a treatment with the methylation-sensitive restriction enzyme. If cytosine in the G pair is not methylated, it is cleaved by the methylation sensitive restriction enzyme.
- genomic DNA contained in biological samples can be obtained by performing PCR using a pair of primers capable of amplifying the target DNA region. If the cytosine in at least one C p G pair existing in the restriction enzyme recognition site in FIG. 4 is not methylated, no PCR amplification product can be obtained. If cytosine in all C p G pairs existing in the recognition site of the methylation-sensitive restriction enzyme in the genomic DNA included is methylated, a PCR amplification product can be obtained. become.
- the first step may be performed as follows.
- Optimal 10X buffer 330 mM Tris-Acetate pH 7.9, 660 mM K0Ac, lOOmM for genomic DNA from mammals
- a preferred embodiment of the methylation sensitive restriction enzyme treatment in the first step is a method of adding a masking oligonucleotide. Specifically, a single-stranded DNA (positive strand) containing the target DNA region is mixed with a masking oligonucleotide consisting of a base sequence complementary to the base sequence of the recognition site of the methylation-sensitive restriction enzyme.
- first (A) step and first (B) step even if the DNA sample derived from the genomic DNA contained in the biological specimen is single-stranded DNA, only double-stranded DNA is used as the substrate. Can be digested with a methylation sensitive restriction enzyme. Also, the first (A) step and the first (B) step may be carried out continuously or simultaneously.
- a “masking oligonucleotide” is an oligonucleotide consisting of a base sequence complementary to the base sequence of the recognition site of a methylation-sensitive restriction enzyme, and several sites contained in the target DNA region in single-stranded DNA Complementary base pairing with at least one site (or all sites) of a recognition sequence of a methyl enzyme-sensitive restriction enzyme forms a duplex (that is, the site is made into a double-stranded state). ) Methylation sensitive restriction enzyme that can digest the above-mentioned site with methylation sensitive restriction enzyme using only double stranded DNA as a substrate. Also, when sample is single stranded DNA, it can digest single stranded DNA.
- Restriction enzymes methylation sensitive restriction enzymes capable of quenching single-stranded DNA can also digest double-stranded DNA, and their digestion efficiency is higher for double-stranded DNA than for single-stranded DNA
- An oligonucleotide of order to be able to improve the efficiency, and duplexes with single-stranded DNA and single-stranded immobilized oligonucleotide comprising a DNA region of interest Means an oligonucleotide that does not inhibit the formation of
- the masking oligonucleotide is an oligonucleotide that cannot be used for the reaction of extending the extension primer, using the reverse primer (positive strand) described below as an extension primer and the masking oligonucleotide (negative strand) as a saddle type.
- the base length is preferably 8 to 200 bases.
- One or more types of masking oligonucleotides may be mixed with a DNA sample derived from genomic DNA. When multiple types are used, many of the recognition sites for the methyl enzyme-sensitive restriction enzyme of the single-stranded DNA containing the target DNA region will be in a double-stranded state. “Uncut NA” can be minimized. For example, the masking oligonucleotide is digested if it is not methylated but not methylated among the recognition sequences of methylation-sensitive restriction enzymes in several locations contained in the target DNA region.
- DNA fragmentation a recognition sequence containing cytosine that is not methylated cannot be completely digested.
- DNA fragmentation a recognition sequence containing cytosine that is not methylated cannot be completely digested.
- DNA sample derived from genomic DNA contained in biological specimen is preferably a DNA sample that has been previously digested with a restriction enzyme that does not use the target DNA region of the genomic DNA as a recognition cleavage site. It can be mentioned as one of the embodiments.
- digested genomic DNA contained in biological samples is immobilized with immobilized oligonucleotides. When selecting, the short vertical DNA is easier to select, and when the target region is amplified by PCR, the shorter vertical DNA is considered to be better.
- Digestion may be carried out by directly using a restriction enzyme with a DNA sample derived from genomic DNA contained in a biological sample, using the DNA region as a recognition cleavage site.
- a general restriction enzyme treatment method may be used as a digestion treatment with a restriction enzyme that does not use the target DNA region as a recognition cleavage site.
- the amount of methylation can be obtained with high accuracy by subjecting the biological specimen itself to the above-described restriction enzyme in advance. This method is useful for eliminating the “DNA residue”.
- a method of digesting a sample derived from genomic DNA contained in a biological sample with a methylation-sensitive restriction enzyme when the biological sample is genomic DNA itself, the same method as described above may be used.
- a large excess of methylation sensitive restriction enzyme for example, 500 fold amount (10 U) or 25 ng DNA amount Digestion treatment may be performed using the above methylation-sensitive restriction enzyme.
- Genomic DNA basically exists as double-stranded DNA. Therefore, in this procedure, not only methylation-sensitive restriction enzymes that can digest single strands (for example, Hhal) but also methyl babies that can digest double-stranded DNA '[ ⁇ live restriction enzymes (for example, HpaII, BstUI, Narl, SacII, Hhal, etc.) can be used.
- the second step can be performed without performing a digestion treatment with a methylation sensitive restriction enzyme capable of digesting single-stranded DNA. If the target DNA region does not contain a base sequence that can be digested with a methylation-sensitive restriction enzyme capable of digesting single-stranded DNA, the second step may be performed without performing the first step.
- a single-stranded DNA subjected to methylation is obtained from the digested DNA sample obtained in the first step, the single-stranded DNA and the immobilized methyl alcohol are obtained.
- D Select single-stranded DNA by binding NA antibody.
- the methylated double-stranded DNA contained in the digested DNA sample obtained in the first step is separated into methylated single-stranded DNA (second ( It may be composed of a step A) and a second step (B) in which the methylated single chain DNA obtained in the second (A) step and the immobilized methylated DNA antibody are bound.
- the methylated double-stranded DNA contained in the digested DNA sample obtained in the first step is converted into a methylated single-stranded DNA.
- a general procedure for converting a double-stranded DNA into a single-stranded DNA may be performed. Specifically, a DNA sample derived from genomic DNA contained in a biological sample may be dissolved in an appropriate amount of ultrapure water, heated at 95 ° C for 10 minutes, and then rapidly cooled in ice.
- the methylated single-stranded DNA is selected from the DNA obtained in the first step by binding with an immobilized methylated DNA antibody.
- Immobilized methylated DNA antibodies are used to select single-stranded DNA that has been methylolated from DNA samples derived from genomic DNA contained in biological specimens.
- the immobilized methyl DNA antibody may be any antibody as long as it can be immobilized on a support, and “immobilized on a support” means that the immobilized methylated DNA antibody is directly attached to the support, or It means that it can be fixed indirectly.
- the immobilized methylated DNA antibody may be immobilized on a support according to a normal genetic engineering operation method or a commercially available kit / equipment (binding to a solid phase).
- a support in which biotinylated immobilized methylated DNA antibody obtained by piotination of immobilized methylated DNA antibody is coated with streptavidin (eg, a PCR tube coated with streptavidin, streptavidin, And a method of fixing to magnetic beads coated with (1).
- streptavidin eg, a PCR tube coated with streptavidin, streptavidin, And a method of fixing to magnetic beads coated with (1).
- a glass whose surface has been activated with a silane coupling agent or the like after covalently binding a molecule having an active functional group such as an amino group, a thiol group, or an aldehyde group to an immobilized methylated DNA antibody.
- a method of covalently bonding to a polysaccharide derivative, silica gel, the synthetic resin, or the like, or a heat-resistant plastic support is also a method in which five units of liglyceride are linked in series by a spacer, a crosslinker or the like.
- the immobilized methylated DNA antibody may be directly immobilized on the support, or the antibody against the immobilized methylated DNA antibody (secondary antibody) is immobilized on the support and the secondary antibody is immobilized. Alternatively, it may be immobilized on a support by binding a methylated antibody.
- the immobilized DNA-immobilized methylated DNA antibody is immobilized on a support.
- (2) after the binding between the single-stranded DNA (positive strand) and the immobilized immobilized methylated DNA antibody, the binding between the immobilized DNA immobilized DNA antibody and the support It may be fixed by.
- the single-stranded DNA is selected.
- a “Piotin-labeled pyotinylated methylcytosine antibody” may be used as an immobilized immobilized methylated DNA antibody as follows.
- washing buffer for example, 0.05% Tween20-containing phosphate buffer (lmM KH 2 P0 4, 3mM Na2HP0 7H20, 154mM NaCl pH7.4) was added at a rate of 100 mu L / tube, and the solution is removed. This washing operation is repeated several times to leave the pyotinylated methylcytosine antibody immobilized on the support in the PCR tube.
- (b) Mix double-stranded DNA derived from genomic DNA contained in a biological sample with a buffer (for example, 33 mM Tris-Acetate pH 7.9, 66 mM K0Ac, lOmM MgOAc 2 , 0.5 mM Dithiothreitol) at 95 ° C. Heat for several minutes. Then, quickly cool to a temperature of about 0-4 ° C and incubate at that temperature for several minutes to form single-stranded DNA. Then return to room temperature.
- a buffer for example, 33 mM Tris-Acetate pH 7.9, 66 mM K0Ac, lOmM MgOAc 2 , 0.5 mM Dithiothreitol
- the biotinylated methylcytosine antibody is immobilized on the formed single-stranded DNA. After that, it is allowed to stand at room temperature for about 1 hour to promote the binding of the pyotinylated methylcytosine antibody to the methylated single chain DNA of the single chain DNA.
- Formation of a conjugate (At this stage, single-stranded DNA containing at least an unmethylated DNA region does not form a conjugate.). After that, the remaining solution is removed and washed.
- Wash buffer eg, phosphate buffer containing 0.05% Tween20 (ImM KH2P04, 3raM Na2HP07H20, 154 mM NaCl pH7.4)
- phosphate buffer containing 0.05% Tween20 ImM KH2P04, 3raM Na2HP07H20, 154 mM NaCl pH7.4
- the buffer used in (b) is not limited to the buffer as long as it is suitable for separating double-stranded DNA derived from biological DNA derived from genomic DNA into single-stranded DNA.
- the washing operations in (a) and (c) were suspended in a solution that was not bound to the immobilized, non-immobilized, methylated DNA antibody or the immobilized methylated DNA antibody that was suspended in the solution. It is important for removing unmethylated single-stranded DNA or DNA floating in a solution digested with restriction enzymes described later from the reaction solution.
- the washing buffer only needs to be suitable for the removal of the above-mentioned free immobilized DNA methylated ring A antibody, single-stranded DNA floating in the solution, and the like. buffer
- a counter oligonucleotide can be added in the second step (A).
- a counter oligonucleotide is obtained by dividing the same base sequence as the target DNA region into short oligonucleotides. The length is usually 10 to 100 bases, more preferably 20 to 50 bases. Counter oligonucleotides should not be designed on base sequences that complementarily base pair with the target DNA region for the forward primer or repurse primer. Counter oligonucleotide is added in a large excess compared to genomic DNA, and the desired DNA region is removed.
- the complementary strand (negative strand) of the target DNA region and the single strand (positive strand) complement the target DNA region. Add to prevent recombination due to sex.
- the target region is a single-stranded methylated DNA antibody. It is because it is easy to combine with.
- the amount of counter oligonucleotide is added at least 10 times, usually 100 times or more, compared to the target DNA region.
- ⁇ Addition of counter oligonucleotide when separating ⁇ -methylated single-stranded DNA '' specifically refers to methylated single DNA from a DNA sample derived from genomic DNA contained in a biological specimen.
- a DNA sample derived from a genomic DNA contained in a biological specimen is mixed with a counter oligonucleotide, and the complementary strand of the target DNA region and the double strand of the counter oligonucleotide are mixed. You should make it.
- the a DNA sample, the counter oligonucleotide, buffer - and (330mM Tris Acetate pH 7.9, 660raM K0Ac, lOOraM MgOAc have 5mM Dithiothreitol) 5 / L, and M g C 1 2 solution 5 L of LOOmM, lm Add 5 L of g / mL BSA solution, add sterilized ultrapure water to the mixture to make 50 ⁇ L, mix, heat at 95 ° C for 10 minutes, and heat to 70 ° C. Cool quickly, hold at that temperature for 10 minutes, then cool to 50 ° C, keep warm for 10 minutes, keep at 37 ° C for 10 minutes, then return to room temperature.
- the single-stranded DNA selected in the second step is separated from the immobilized DNA antibody, and free single-stranded DNA is separated.
- the first step first previous step
- the double-stranded DNA formed by extension in the second previous step contains a single-stranded DNA (positive strand) containing the target DNA region and a base sequence that is complementary to the target DNA region. It has a process (third pre-process) that separates into single-stranded DNA (negative chain) once.
- Step A (this step) in which a single-stranded DNA containing the target DNA region is elongated as a double-stranded DNA;
- a single-stranded DNA (negative strand) containing a base sequence that is complementary to the generated target DNA region in a saddle shape, and a base that is complementary to the target DNA region A partial base sequence (negative strand) of the base sequence of the single-stranded DNA (negative strand) containing the sequence, and complementary to the base sequence (positive strand) of the target DNA region.
- An extension primer having a base sequence (positive strand) complementary to a partial base sequence (negative strand) located further 3 'than the 3' end of a base sequence (negative strand) (a reverse primer) )
- a step B this step in which the single-stranded DNA containing the target DNA region is formed as a double-stranded DNA.
- each step of the third step is repeated after separating the elongated double-stranded DNA obtained in each step into a single-stranded state, and then repeating the above steps. Amplify the methylated DNA in to a detectable amount and quantify the amount of amplified DNA.
- the single-stranded DNA selected in the second step is first separated from the immobilized and immobilized methylated DNA antibody as a first pre-step of the following steps of each of the following steps.
- Set to DNA A which is in the main chain state. Specifically, for example, an annealing buffer is added to the single-stranded DNA selected in the second step to obtain a mixture.
- the resulting mixture is heated at 95 ⁇ for several minutes to obtain single-stranded DNA (positive strand). Thereafter, in the second pre-process, specifically, for example, the single-stranded DNA (positive strand) obtained in the first pre-process and the forward primer are used, and sterile ultrapure water is used at 17.85 ⁇ L.
- an annealing buffer is added to the double-stranded DNA extended and formed in the second pre-process to obtain a mixture, and the resulting mixture is obtained. By heating to 95 ° C for several minutes, once to the single-stranded DNA containing the desired DNA region. To away.
- the Tm value of the forward primer is about 0 to Cool quickly to a temperature lower by 20 ° C and keep at that temperature for several minutes
- the single-stranded DNA annealed in the above (i) is used as a saddle type, the primer for extension is used as an extension primer, and the primer is extended once.
- a single-stranded DNA containing a base sequence that is complementary to the DNA region to be extended is formed as a double-stranded DNA (ie, step A). Specifically, for example, it may be carried out according to the following description or the operation method in the extension reaction in the second previous step of the present invention described above.
- a single-stranded DNA (negative strand) containing a base sequence complementary to the generated target DNA region is used as a saddle, and the single-stranded DNA containing the target DNA region (A) A partial base sequence (negative strand) of the base sequence possessed by the negative strand and complementary to the base sequence (positive strand) of the target DNA region A partial base sequence (negative strand) located further to the 3 'end side than the 3' end, a base sequence that is complementary to (
- the extension primer (reverse primer) having a positive strand as an extension primer and extending the extension primer once, the single-stranded DNA is converted into a double-stranded DNA that has been formed.
- Step B it may be carried out according to the operation method in the extension reaction in the second previous step, as in the step A of (iii) above.
- each step in the third step is repeated after separating the elongated double-stranded DNA obtained in each step into a single-stranded state (for example, step A and step A).
- step B the methylated DNA in the target DNA region is amplified to a detectable amount, and the amount of amplified DNA is quantified.
- the reaction from the first pre-step to the main step can be carried out as one PCR reaction. Further, it is also possible to carry out each of the first pre-process to the third pre-process as an independent reaction, and to perform only this process as a PCR reaction.
- PCR can be used as a method for amplifying the target DNA region (ie, the target region) contained in the selected single-stranded DNA.
- a target region is amplified, by using a primer previously labeled with fluorescence or the like and using the label as an index, the presence or absence of an amplification product can be evaluated without performing troublesome operations such as electrophoresis.
- PCR reaction solution for example, DNA obtained in the second step of this effort, 0.15 ⁇ 1 of 50 ⁇ primer solution, 2.5 ⁇ 1 of 2 mM dNTP, 10 ⁇ buffer solution (lOOmM Tris-HC1 pH 8.3, and 500mM KC1, 20mM MgCl 2, 0.01 % Gelatin) to 2.5 ⁇ 1, AmpliTaq Gold (one kind of thermostable DNA polymerase: 5U / 1) were mixed and 0.2 ⁇ 1 the liquid added with sterile ultrapure water A reaction liquid whose amount is 25 1 can be mentioned.
- the reaction may be carried out by adding an appropriate amount of betaine, DMSO, etc. at times.
- the above reaction solution is kept at 95 ° C. for 10 minutes, then at 95 ° C. for 30 seconds and then at 55 to 65 ° C. for 30 seconds and further to 72 ° C. 30 to 40 cycles of heat insulation with 30 seconds as one cycle
- the conditions to perform are mentioned.
- the obtained amplification product is detected.
- the amplification amount in the PCR reaction can be evaluated by measuring the amount of the fluorescent label after performing the same washing and purification operation as before.
- PCR when PCR is performed using normal unlabeled primers, detection is performed by annealing the gold colloid particles, probes labeled with fluorescence, etc., and measuring the amount of the probe bound to the target region. can do.
- real-time PCR may be used to obtain the amount of amplification product more accurately.
- the real-time PCR method is a method that monitors the PCR in real time and analyzes the obtained monitoring results by force kinetics. For example, it can detect even a slight difference of about twice the gene amount. This method is known as the quantitative PCR method.
- Examples of the real-time PCR method include a method using a probe such as a cage-type nucleic acid polymerase probe, a method using an inter forceator such as Cyber Green, and the like. Commercially available equipment and kits for real-time PCR may be used.
- the detection is not particularly limited, and detection by any method known so far is possible. In these methods, operations up to detection can be performed without changing the reaction vessel.
- the present invention may be used in the following situations.
- genomic DNA contained in a biological specimen derived from a disease there is a DNA region that is 100% methylated in genomic DNA contained in a biological specimen derived from a disease, and if the present invention is carried out for that DNA region, the amount of methylated DNA increases.
- the genomic DNA contained in a biological sample from a healthy person is hypomethylated, and the genome contained in a biological sample from a diseased patient.
- DNA region that is hypermethylated in DNA there is a DNA region that is hypermethylated in DNA.
- the amount of methylated DNA in a healthy person is:
- the value is significantly higher than the value in the case of a healthy person, so the “degree of disease” can be determined based on the difference in this value.
- the “degree of disease” here has the same meaning as that generally used in the field, and specifically means, for example, the malignancy of the cell when the biological specimen is a cell.
- the biological specimen is a tissue, it means the abundance of disease cells in the tissue.
- the biological specimen is plasma / serum, it means the probability that the individual has a disease.
- the present invention makes it possible to diagnose various diseases by examining methylation abnormalities.
- restriction enzymes, primers or probes that can be used in various methods for measuring the amount of methylated DNA in the target region in the present invention are useful as reagents for detection kits.
- the present invention also provides a detection kit containing these restriction enzymes, primers or probes as reagents, and a detection chip in which these primers or probes are immobilized on a support,
- the scope of rights of the present invention or the methylation ratio measurement method of the present invention includes use in the form of a detection kit or a detection chip as described above utilizing the substantial principle of the method.
- ⁇ Partially methylated oligonucleotide having a methylated recognition sequence of HpaI I> N represents 5-methylcytosine.
- GGGATCGTCACACTCGTCGTGC -3 ′ (SEQ ID NO: 17) Partially methylated oligonucleotide> N in which the recognition sequence of HpaI I is not methylated represents 5-methylcytosine.
- a treatment group (no treatment group): Buffer (330raM Tris-Acetate pH 7.9, 660 mM K0Ac, lOOniM MgOAc 2 , 5 mM Dithiothreitol) 5 ⁇ and B SA (Bovine serum albumin lmg / mL) was added to 5 L, and sterilized ultrapure water was added to the mixture to make the volume 50 ⁇ L.
- Buffer 330raM Tris-Acetate pH 7.9, 660 mM K0Ac, lOOniM MgOAc 2 , 5 mM Dithiothreitol
- B SA Bovine serum albumin lmg / mL
- Hpa II treated group 5 ⁇ L of buffer solution (330 mM Tris-Acetate pH 7.9, 660 mM K0Ac, lOOmM MgOAc 5 mM Dithiothreitol) and B SA (Bovine serum albumin lmg) / mL) was added to 5 / L and Hpa II was added to 10 U, and sterilized ultrapure water was further added to the mixture to adjust the volume to 50 ⁇ L.
- buffer solution 330 mM Tris-Acetate pH 7.9, 660 mM K0Ac, lOOmM MgOAc 5 mM Dithiothreitol
- B SA Bovine serum albumin lmg
- Group C (masking oligonucleotide added + Hpa II treatment group): 5 / L of buffer solution (330 mM Tris-Acetate pH 7.9, 660 mM K0Ac, lOOmM MgOAc 2 , 5 mM Dithiothreitol) was added to the sample prepared above. Add 5 p mo 1 as a masking oligonucleotide to 5 L of BSA (Bovine serum albumin lmg / ml), 5 U of Hpa II, 10 U of Hpa II, and the nucleotide sequence shown in SEQ ID NO: 20, and then mix the mixture. Sterile ultrapure water was added to the mixture to make the volume 5 L. Gus masking oligonucleotides>
- PR 1 5 GCACGACGAGTGTGACGATC-3 (SEQ ID NO: 22)
- the PCR reaction solution was prepared by adding a primer solution consisting of the base sequence shown in SEQ ID NO: 21 and a primer solution consisting of the base sequence shown in SEQ ID NO: 22 prepared in 3 M to the vertical DNA.
- methylcytosine antibody manufactured by Aviva Systems Biology
- pyotinylated kit Biotin Labeling Kit-NH2, manufactured by Dojindo Laboratories
- PR 2 5 '-CTGGCCAAACTGGAGATCGC -3' (SEQ ID NO: 25)
- PCR reaction solution 5 ⁇ g of genomic DNA to be ⁇ type and 3 ⁇ 1 each of oligonucleotide primer solution prepared to 5 ⁇ , 5 ⁇ each 2 mM dNTP, 10 X buffer solution (LOOmM Tris-HCl pH 8.3, 500 mM KC1, 15 mM MgCl 2 , 0.01% Gelatin) 5 ⁇ 1 and metathermal DNA polymerase (AmpliTaq Gold, AB I) 5U / U mixed with 0.25 1 Then, sterilized ultrapure water was added to make the volume 50 1. The reaction solution is kept at 95 ° C for 10 minutes, then at 95 ° C for 30 seconds, then at 61 ° C for 30 seconds, and further at 72 ° C for 45 seconds for one cycle for 40 cycles. PCR was performed under conditions.
- DNA fragment X was purified by Wizard SV Gel / PCR Kit (PR0MEGA). About a part of the obtained DNA fragment solution, Sssl methylase (manufactured by NEB) 1 ⁇ 1, 10 xNEBuffer2 (manufactured by NEB) 10 1, S- adenosyl methionine (3.2 mM, NEB) was mixed with 1 1, and sterilized ultrapure water was added thereto to adjust the volume to 100 1.
- Sssl methylase manufactured by NEB
- 10 xNEBuffer2 manufactured by NEB
- S- adenosyl methionine 3.2 mM, NEB
- Solution A 100pg / 5 / zL TE solution
- Solution B 10pg / 5L TE solution
- Solution D TE solution (negative control solution)
- TE solution negative control solution
- Solution MA 100pg / 5L TE solution
- Counter oligonucleotide C 1 consisting of the nucleotide sequences shown in SEQ ID NO: 29 to SEQ ID NO: 40 each capable of base pairing by complementarity to the negative strand of the target DNA region X ′ consisting of the nucleotide sequence shown in SEQ ID NO: 28 ⁇ C 12 was synthesized, and a TE buffer solution having a concentration of 0.01 was prepared.
- the PCR tube was heated at 95 ° C. for 10 minutes, rapidly cooled to 70 ° C., and kept at that temperature for 10 minutes.
- the mixture was cooled to 50 ° C., kept warm for 10 minutes, further kept at 37 ° C. for 10 minutes, and then returned to room temperature (this corresponds to the second step of the measurement method of the present invention).
- the DNA fragment reaction solution 50 prepared above was added to the streptavidin-coated PCR tube on which the biotin-labeled methylcytosine antibody had been immobilized, and left at room temperature for 30 minutes. Thereafter, the solution was removed by pipetting, 1 ⁇ 0 mu L of the washing puffer [0.
- PR 2 5 '-CTGGCCAAACTGGAGATCGC -3' (SEQ ID NO: 25)
- GGCCAG-3 ′ (SEQ ID NO: 28)
- a reaction solution for PCR the DNA of the vertical shape, 3 L each of oligonucleotide primer solution prepared at 5 / M, each 2 mM dNTP, and buffer solution ( Mix 5 L of lOOmM Tris-HCl pH 8.3, 500 mM KC1 15 mM MgCl 2 0.01% Gelatin) and metathermic DNA polymerase (AmpliTaq Gold AB I) 5 ⁇ / ⁇ with 0.25 ⁇ L. The solution was adjusted to 50 by adding sterilized ultrapure water. Incubate the reaction solution at 95 ° C for 10 minutes, then heat at 95 ° C for 20 seconds, then at 61 ° C for 30 seconds, and then at 72 ° C for 30 seconds for one cycle for 25 cycles.
- a commercially available methylcytosine antibody (Aviva, Systems Biology) was biotin-labeled using a commercially available pyotinylated kit (Biotin Labeling Kit_NH2, manufactured by Dojindo Laboratories) according to the method described in the catalog.
- Solution of the resulting biotin-labeled methylcytosine antibody [Phosphate buffer (ImM KH 2 P0 4 , 3niM Na 2 HP0 70, 154raM NaCl pH7.4) solution containing approximately 0.25 ⁇ g / VL 0, 1% BSA] As refrigerated.
- Streptavidin-coated PCR tubes (total of 8 tubes) were added with 0.1 ⁇ / 50 / b solution of biotin-labeled methylcytosine antibody obtained by synthesis at a rate of 50 ° C for about 1 hour. It was allowed to stand at room temperature and immobilized on a PCR tube. Then, the solution was removed by pipetting, and a lOO ⁇ L wash buffer [0.05% Tween20-containing phosphate buffer (lmM KH 2 P0 4 , 3 mM Na 2 HP0 7H 20 , 154raM NaCl pH 7.4)] was added. Thereafter, the buffer was removed by pipetting.
- DNA fragment Y was purified by Wizard SV Gel / PCR Kit (PR0MEGA).
- Sssl methylase manufactured by NEB
- 10 x NEBuffer 2 manufactured by NEB
- S- adenosyl methionine 3.2 nil, NEB3 ⁇ 4t®
- Solution A 100pg / 5 ⁇ L TE solution
- Solution B 10pg / 5L TE solution
- Solution D TE solution (negative control solution) The following solution was prepared for the obtained DNA fragment MY.
- the PCR tube was heated at 95 ° C for 10 minutes, rapidly cooled to 70 ° C, and kept at that temperature for 10 minutes. Next, it was cooled to 50 ° C and kept for 10 minutes, further kept at 37 ° C for 10 minutes, and then returned to room temperature (this corresponds to the second step of the measurement method of the present invention).
- the DNA fragment reaction solution 50 prepared above was added to the streptavidin-coated PCR tube immobilized with the above-mentioned piotin-labeled methylcytosine antibody, and the mixture was allowed to stand at room temperature for 30 minutes.
- PCR is performed in the above PCR tube using each solution of oligonucleotide primers PF3 and PR3 consisting of the base sequences represented by SEQ ID NO: 41 and SEQ ID NO: 42, respectively, using the following reaction conditions:
- oligonucleotide primers PF3 and PR3 consisting of the base sequences represented by SEQ ID NO: 41 and SEQ ID NO: 42, respectively, using the following reaction conditions:
- methylated DNA in the target DNA region Y ′ consisting of the base sequence represented by SEQ ID NO: 45 was amplified.
- PCR reaction solution we prepared 3 ⁇ L each of oligonucleotide primer solution prepared in 5 ⁇ , 5 each 2 mM dNTP, and buffer solution (lOOmM Tris-HCl pH 8.3, 500 mM KC1). , 15 mM MgCl, 0.01% Gelatin); 5 uL, Metathermal DN A polymerase (AmpliTaq Gold, manufactured by AB I)! ! / Mix with 25 / zL Then, sterilized ultrapure water was added to make the volume 50 / ⁇ L. Incubate the reaction solution at 95 ° C for 10 minutes, then heat at 95 ° C for 20 seconds, then at 60 ° C for 30 seconds, and then at 72 ° C for 30 seconds for one cycle for 25 cycles. PCR was performed under conditions.
- a commercially available methylcytosine antibody (manufactured by Aviva Systems Biology) was labeled using a commercially available pyotinylated kit (Biotin Labeling Kit-NH2, manufactured by Dojindo Laboratories) according to the method described in the catalog.
- the obtained biotin-labeled methylcytosine antibody was refrigerated and stored as a solution [an antibody of about 0.25 / 0.1% BSA-containing phosphate buffer (lmM KH 2 P0 4 , 3raM Na 2 HP0 73 ⁇ 40, 154 mM NaCl pH 7.4) solution].
- the baker's yeast strain X 2180-1 A in YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6-6.0) has a turbidity of 0D 6 . .
- the cells were cultured until 0.6-1.0, and centrifuged at 10, OOOg for 10 minutes to prepare lxlO 7 yeast cells. From the prepared yeast cells, the yeast genome was obtained using a general yeast genome preparation method as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).
- PCR was performed using the oligonucleotide primers (PF 4 and PR 4) represented by SEQ ID NO: 49 and SEQ ID NO: 50, respectively, and the following reaction conditions.
- PF 4 and PR 4 oligonucleotide primers represented by SEQ ID NO: 49 and SEQ ID NO: 50, respectively, and the following reaction conditions.
- T a DNA fragment (T, a region corresponding to base number 384569-384685 of yeast chromosome VII shown in SEQ ID NO: 51, Genbank Accession No. NC-001139, etc.) used as a test sample was amplified.
- PCR reaction solution 10 ng of the genomic DNA in the shape of a cage, 3 1 each of oligonucleotide primer solution prepared in 5 ⁇ , each 2 mM (1 ⁇ 1 ?? 5 1 and 10 X Buffer 5 (lOOraM Tris-HCl pH 8.3, 500 mM KC1, 15raM MgCl 2 , 0.01% Gelatin) 5 ⁇ 1 and thermostable DNA polymerase (AmpliTaq Gold, AB I) 511/1 0.25 ⁇ 1 And sterilized ultrapure water was added to adjust the volume to 50. 1. The reaction solution was kept at 95 ° C for 10 minutes and then heated to 95 ° C. Then, PCR was performed for 20 seconds, followed by 40 cycles of incubation at 58 ° C for 30 seconds and 72 ° C for 30 seconds.
- DNA fragment T was purified by Wizard SV Gel / PCR Kit (PR0MEGA). About a part of the obtained DNA fragment solution, 1 ⁇ 1 of Sssl methylase (manufactured by NEB), 10 ⁇ m of 10 x NEBuffer 2 (manufactured by NEB), and S-adenosyl methionine (3.2 ⁇ , NEB) 1) was mixed with 1 ⁇ 1 and sterilized ultrapure water was added thereto to adjust the volume to 100 ⁇ 1. Incubate the reaction at 37 ° C for 15-30 minutes.
- Sssl methylase manufactured by NEB
- 10 ⁇ m of 10 x NEBuffer 2 manufactured by NEB
- S-adenosyl methionine 3.2 ⁇ , NEB
- Solution A 100pg / 5 a L TE solution
- Solution B lOpg / S ⁇ L TE solution
- Solution D TE solution (negative control solution) The following solution was prepared for the obtained DNA fragment MT.
- Solution MA 100 ⁇ ⁇ / 5 ⁇ TE solution
- Solution MD TE solution (negative control solution)
- buffer solution 330 mM Tris-Acetate pH 7.9, 660 mM KOAc ⁇ lOOniM MgOAc 5 mM Dithiothreitol
- B SA Bovine serum albumin lmg / ml
- H pa II 12U methylation sensitive restriction enzyme
- Counter oligonucleotide C 16 consisting of the base sequences shown in SEQ ID NO: 54 to SEQ ID NO: 57 each capable of base pairing by complementarity to the negative strand of the target DNA region T ′ consisting of the base sequence shown in SEQ ID NO: 53 ⁇ C19 was synthesized, and a TE buffer solution having a concentration of 0.01 / XM was prepared.
- the PCR tube was heated at 95 ° C for 10 minutes, rapidly cooled to 70 ° C, and kept at that temperature for 10 minutes. Next, it was cooled to 50 ° C, kept for 10 minutes, further kept at 37 for 10 minutes, and then returned to room temperature (this corresponds to the second step of the measurement method of the present invention).
- 50 L of the DNA fragment reaction solution prepared above was added to the streptavidin-coated PCR tube to which the biotin-labeled methylcytosine antibody had been immobilized, and left at room temperature for 30 minutes.
- washing buffer [0.05% Tween20-containing phosphate buffer (ImM KH 2 P0 4 , 3 mM Na 2 HP0 7H 20 , 154raM NaCl pH7.4)] The buffer was removed by pipetting. This operation was repeated twice more (this corresponds to the third step of the measurement method of the present invention).
- PCR is performed on the above-mentioned PCR tube using each solution of oligonucleotide primers PF4 and PR4 each consisting of the nucleotide sequences represented by SEQ ID NO: 49 and SEQ ID NO: 50, and the following reaction conditions:
- the methylated DNA in the target DNA region T ′ consisting of the base sequence represented by SEQ ID NO: 53 was amplified.
- PR 4 5 '-AGTACAGATCTGGCGTTCTCG-3' (SEQ ID NO: 50)
- the baker's yeast strain X 2180-1 A in YPD medium (1 ° /. Yeast extract, 2% Peptone, 2% Glucose, pH 5.6-6.0) has a turbidity of 0D 6 . .
- the cells were cultured until 0.6-1.0, and centrifuged at 10, OOOg for 10 minutes to prepare lxlO 7 yeast cells. From the prepared yeast cells, the yeast genome was obtained using a general white yeast genome preparation method as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).
- the prepared yeast cells are suspended in buffer A (1M sorbitol, 0.1M EDTA, pH 7.4), 0.1% 2_mercaptoethanol (final concentration 14 mM) and 100 zymolase (10 mg / ml) are added to the solution. Incubate with stirring at 30 ° C for 1 hour until clear. Protoplasts are collected by centrifugation at 550 g for 10 minutes, suspended in Notfer B (50 mM Tris-HC1, pH 7.4, 20 mM EDTA), and sodium dodecyl sulfate is added to 1% (w / v). And then incubated at 65 ° C for 30 minutes. Subsequently, 2/5 volume ratio of 5M C3 ⁇ 4C00K was added and mixed.
- buffer A 1M sorbitol, 0.1M EDTA, pH 7.4
- 2_mercaptoethanol final concentration 14 mM
- 100 zymolase 10 mg / ml
- Solution A lOng / 5 / zL TE solution
- Solution B Ing / 5 W L TE solution
- Solution D TE solution (negative control solution)
- TE solution negative control solution
- Solution MA lOng / 5 iL TE solution
- Solution MD TE solution (negative control solution) The following treatment was applied to each of the above-mentioned yeast genome DNA solution and methylated yeast genome DNA solution.
- a PCR tube In a PCR tube, add the genomic DNA solution 5 prepared above, 5 U of the restriction enzyme X sp I, and 10 x buffer (200 mM Tris-HCl pH 8.5, lOOmM MgCl 2 , lOmM Dithiothreitol, lOOOmM) KC1) ⁇ ⁇ was mixed and sterilized ultrapure water was added to prepare a solution volume of 10 ⁇ 1. The reaction solution was incubated at 37 ° C for 1 hour.
- 10 x buffer 200 mM Tris-HCl pH 8.5, lOOmM MgCl 2 , lOmM Dithiothreitol, lOOOmM
- buffer solution 330 mM Tris-Acetate H 7.9, 660 mM K0Ac, lOOmM MgOAc 2 , 5 mM Dithiothreitol
- BSA Bovine serum albumin lmg / ml
- methylation sensitive restriction enzyme 12 U of H pa II was added, and sterilized ultrapure water was further added to the mixture to make a volume of 20 ⁇ L. Each mixture was incubated at 37 for 3 hours. Equivalent to one step).
- a counter oligonucleotide solution 10 L was prepared, a buffer solution and (330mM Tris- Acetate pH 7.9, 66O111M K0Ac, lOOmM MgOAc have 5mM Dithiothreitol) 5 ⁇ L, and M g C 1 2 solution LOOmM, 1111 ⁇ / 1111 ⁇ : 83 A solution 5 L was added, and further sterilized ultrapure water was added to the mixture to make the volume 50 L and mixed. Thereafter, the PCR tube was heated at 95 ° C for 10 minutes, rapidly cooled to 70 ° C, and kept at that temperature for 10 minutes. Next, it was cooled to 50 ° C and kept for 10 minutes, further kept at 37 ° C for 10 minutes, and then returned to room temperature (this corresponds to the second step of the measurement method of the present invention).
- PCR was carried out in the above PCR tube using a solution of each of the oligonucleotide primers PF 4 and PR 4 consisting of the base sequences represented by SEQ ID NO: 49 and SEQ ID NO: 50, and the following reaction conditions:
- the methylated DNA in the target DNA region T which consists of the nucleotide sequence shown in SEQ ID NO: 53, was amplified.
- PCR reaction solution As the PCR reaction solution, mirror-type DNA was added to each 5 ml of oligonucleotide primer solution prepared at 5 M, each 2 mM dNTP 5 L, buffer ( ⁇ ⁇ Tris-HCl pH 8.3, 500 raM KC1, 15 mM MgCl 2 , 0.01% Gelatin) 5 / zL, metathermic DNA polymerase (AmpliTaq Gold, manufactured by AB I) 511 and 0.25 / zL were mixed with sterilized ultrapure water. The liquid volume was 50. Incubate the reaction solution at 95 ° C for 10 minutes, then heat at 95 ° C for 20 seconds, then at 58 ° C for 30 seconds, and further at 72 ° C for 30 seconds, with 31 cycles. PCR was performed under conditions.
- Designed oligonucleotide consisting of the desired DNA region (GPR7-2079-2176) SEQ ID NO: 2 4
- Amplified oligonucleotide consisting of the target DNA region (Genbank Accession No. NT 029419 25687390-25687775 homosapiens)
- SEQ ID NO: 2 7 Designed oligonucleotide consisting of the target DNA region (Genbank Accession No. NT— 029419 25687390-25687775 homo sapiens), n 2 m5c
- Designed oligonucleotide consisting of the desired DNA region (Genbank Accession No. NT_029419 25687390-25687775 homo sapiens)
- Amplified oligonucleotide consisting of the desired DNA region (Genbank Accession No. AC009800 76606-76726 homosapiens)
- n m5c
- Amplified oligonucleotide consisting of the desired DNA region (Genbank Accession No. NC001139 384569—384685 Saccharomyces cerevisiae chromo, Nome VII)
- n m5c
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200980118263XA CN102037140A (zh) | 2008-03-25 | 2009-03-25 | Dna甲基化测定方法 |
US12/934,823 US20110262912A1 (en) | 2008-03-25 | 2009-03-25 | Method for measuring dna methylation |
EP20090725639 EP2272975B1 (en) | 2008-03-25 | 2009-03-25 | Method for determination of dna methylation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-077967 | 2008-03-25 | ||
JP2008077967A JP5266828B2 (ja) | 2008-03-25 | 2008-03-25 | メチル化されたdnaの含量を測定する方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009119891A1 true WO2009119891A1 (ja) | 2009-10-01 |
Family
ID=41114071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/056785 WO2009119891A1 (ja) | 2008-03-25 | 2009-03-25 | Dnaメチル化測定方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110262912A1 (ja) |
EP (1) | EP2272975B1 (ja) |
JP (1) | JP5266828B2 (ja) |
KR (1) | KR20100130223A (ja) |
CN (1) | CN102037140A (ja) |
WO (1) | WO2009119891A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012095642A (ja) * | 2010-10-06 | 2012-05-24 | Sumitomo Chemical Co Ltd | 哺乳動物由来の検体の癌化度を評価する方法 |
JP2012095643A (ja) * | 2010-10-06 | 2012-05-24 | Sumitomo Chemical Co Ltd | 哺乳動物由来の検体の癌化度を評価する方法 |
JP2012075427A (ja) * | 2010-10-06 | 2012-04-19 | Sumitomo Chemical Co Ltd | 哺乳動物由来の検体の癌化度を評価する方法 |
JP2012075426A (ja) * | 2010-10-06 | 2012-04-19 | Sumitomo Chemical Co Ltd | 哺乳動物由来の検体の癌化度を評価する方法 |
RU2666910C1 (ru) * | 2014-11-07 | 2018-09-13 | ДжНА БИОСОЛЮШЕНЗ ГМБХ | Способ суперамплификации с пцр |
US20180237824A1 (en) * | 2014-11-10 | 2018-08-23 | Gna Biosolutions Gmbh | Method for multiplying nucleic acids |
CN105018617A (zh) * | 2015-07-20 | 2015-11-04 | 浙江大学 | 单个基因mRNA甲基化水平检测方法 |
CN109234388B (zh) * | 2017-07-04 | 2021-09-14 | 深圳华大生命科学研究院 | 用于dna高甲基化区域富集的试剂、富集方法及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007119518A1 (ja) * | 2006-03-28 | 2007-10-25 | The University Of Tokyo | 抗メチル化dna抗体及びその作製方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002246612B2 (en) * | 2000-10-24 | 2007-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Direct multiplex characterization of genomic DNA |
WO2006056478A1 (en) * | 2004-11-29 | 2006-06-01 | Klinikum Der Universität Regensburg | Kits and methods for detecting methylated dna |
US7906288B2 (en) * | 2006-01-04 | 2011-03-15 | The Johns Hopkins University | Compare-MS: method rapid, sensitive and accurate detection of DNA methylation |
JP5277681B2 (ja) * | 2007-03-26 | 2013-08-28 | 住友化学株式会社 | Dnaメチル化測定方法 |
JP5303981B2 (ja) * | 2007-03-26 | 2013-10-02 | 住友化学株式会社 | Dnaメチル化測定方法 |
-
2008
- 2008-03-25 JP JP2008077967A patent/JP5266828B2/ja not_active Expired - Fee Related
-
2009
- 2009-03-25 CN CN200980118263XA patent/CN102037140A/zh active Pending
- 2009-03-25 KR KR1020107023696A patent/KR20100130223A/ko not_active Application Discontinuation
- 2009-03-25 WO PCT/JP2009/056785 patent/WO2009119891A1/ja active Application Filing
- 2009-03-25 EP EP20090725639 patent/EP2272975B1/en not_active Not-in-force
- 2009-03-25 US US12/934,823 patent/US20110262912A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007119518A1 (ja) * | 2006-03-28 | 2007-10-25 | The University Of Tokyo | 抗メチル化dna抗体及びその作製方法 |
Non-Patent Citations (13)
Title |
---|
"Methods in Yeast Genetics", COLD SPRING HARBOR LABORATORY |
ALLEN, R. CUTLER ET AL.: "Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation.", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 51, no. 6, 1992, pages 1229 - 1239, XP008143271 * |
BUCKLE, MALCOLM. ET AL.: "Real time measurements of elongation by a reverse transcriptase using surface plasmon resonance.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 2, 1996, pages 889 - 894, XP002252240 * |
GRUENBAUM ET AL., NUCLEIC ACID RESEARCH, vol. 9, pages 2509 - 2515 |
HEISKANEN, MERVI ET AL.: "A novel method to quantitate methylation of specific genomic regions.", PCR METHODS AND APPLICATIONS, vol. 4, no. 1, 1994, pages 26 - 30, XP000465079 * |
NUCLEIC ACIDS RES., vol. 22, no. 15, 11 August 1994 (1994-08-11), pages 2990 - 7 |
NYGREN, ANDERS O. H. ET AL.: "Methylation- specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences.", NUCLEIC ACIDS RESEARCH, vol. 33, no. 14, 2005, pages E128 - 1-9, XP002596755 * |
PROC. NATL. ACAD. SCI. U.S.A., vol. 94, no. 6, 18 March 1997 (1997-03-18), pages 2284 - 9 |
SCHMIDT, PETER M. ET AL.: "Detection of activity of telomerase in tumor cells using fiber optical biosensors.", BIOSENSORS & BIOELECTRONICS, vol. 17, no. 11-12, 2002, pages 1081 - 1087, XP001206070 * |
SHIN SEIKAGAKU JIKKEN KOZA 2 KAKUSAN I -BUNRI SEISEI, 1991, TOKYO, pages 169 - 172, 180, XP008150058 * |
STERKY, FREDRIK ET AL.: "Direct sequencing of bacterial artificial chromosomes (BACs) and prokaryotic genomes by biotin-capture PCR.", JOURNAL OF BIOTECHNOLOGY, vol. 60, no. 1-2, 1998, pages 119 - 129, XP004115549 * |
TONG, YU K. ET AL.: "Detection of restriction enzyme-digested target DNA by PCR amplification using a stem-loop primer: application to the detection of hypomethylated fetal DNA in maternal plasma.", CLINICAL CHEMISTRY, vol. 53, no. 11, 2007, pages 1906 - 1914, XP008132142 * |
YARMUSH, MARTIN L. ET AL.: "Immunoadsorption: strategies for antigen elution and production of reusable adsorbents.", BIOTECHNOLOGY PROGRESS, vol. 8, no. 3, 1992, pages 168 - 178, XP008143270 * |
Also Published As
Publication number | Publication date |
---|---|
EP2272975A4 (en) | 2011-06-29 |
KR20100130223A (ko) | 2010-12-10 |
EP2272975A1 (en) | 2011-01-12 |
US20110262912A1 (en) | 2011-10-27 |
JP2009225760A (ja) | 2009-10-08 |
CN102037140A (zh) | 2011-04-27 |
EP2272975B1 (en) | 2015-04-22 |
JP5266828B2 (ja) | 2013-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110189674A1 (en) | Method for quantifying or detecting dna | |
WO2009119891A1 (ja) | Dnaメチル化測定方法 | |
JP2010017179A (ja) | Dnaを定量又は検出する方法 | |
US20110143348A1 (en) | Method for quantifying or detecting dna | |
JP5206059B2 (ja) | メチル化されたdnaの含量を測定する方法 | |
JP4924014B2 (ja) | Dnaメチル化測定方法 | |
JP5303981B2 (ja) | Dnaメチル化測定方法 | |
JP5211790B2 (ja) | Dnaメチル化測定方法 | |
JP5277681B2 (ja) | Dnaメチル化測定方法 | |
WO2008099745A1 (ja) | Dnaメチル化測定方法 | |
JP5151709B2 (ja) | Dnaを定量又は検出する方法 | |
JP4940939B2 (ja) | Dnaメチル化測定方法 | |
JP4940940B2 (ja) | Dnaメチル化測定方法 | |
JP2013074837A (ja) | 哺乳動物由来の検体の癌化度を評価する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980118263.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09725639 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6742/CHENP/2010 Country of ref document: IN Ref document number: 2009725639 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107023696 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12934823 Country of ref document: US |